DRNA News and Press, Dicerna Pharmaceuticals Inc. From 06/08/21

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded today at $33.73, eclipsing its 52-week high. This new high was reached on below average trading volume as 124,000 shares traded hands, while the average 30-day volume is approximately 711,000 shares. Dicerna Pharmaceuticals Inc....

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, w...

Dicerna Pharmaceuticals (DRNA) announces that the U.S. FDA has accepted the Investigational New Drug (“IND”) application filed by Eli Lilly (LLY) for LY3819469, which is a potential treatment of cardiometabolic diseases.LY3819469, which is an investigational ...

– Second GalXC™ RNAi Investigational New Drug (IND) Application Filed by Lilly Under Companies’ Global Research Collaboration and Licensing Agreement – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicern...

Development Candidate Will Be Evaluated for Treatment of Nonalcoholic Steatohepatitis Candidate Selection Triggers Single-Digit Multimillion USD Milestone Payment to Dicerna Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dice...

Dicerna approached doubling from its 52-week low, then drifted lower recently. Cash was raised recently from a royalty deal; has a runway to 2024. The platform and pipeline remain poised for long-term value. For further details see: Dicerna A Buy On Long-Term Potential ...

Dicerna Pharmaceuticals, Inc. (DRNA) Q1 2021 Earnings Conference Call May 06, 2021, 04:30 PM ET Company Participants Will Grammig - Stern IR Doug Fambrough - President, CEO Doug Pagan - CFO Sheeram Aradhye - CMO Jim Weissman - COO Rob Ciappenelli - CCO Bob Brown - CSO Shreeram Aradhye - EVP &...

Image source: The Motley Fool. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) Q1 2021 Earnings Call May 6, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Dicerna Pharmaceuticals Inc (DRNA) Q1 2021 Earnings Call Transcr...

Dicerna Pharmaceuticals (DRNA) posted a 40% rise in first-quarter revenue and said that it expects its cash and cash equivalents to help fund the company's operations into 2024.The company's quarterly revenue increased 40% to $47.6M, owing to a rise in services performed under the c...

Dicerna Pharmaceuticals (DRNA): Q1 GAAP EPS of -$0.39 misses by $0.02.Revenue of $47.6M (+39.9% Y/Y) misses by $1.46M.Press Release For further details see: Dicerna Pharmaceuticals EPS misses by $0.02, misses on revenue